Epizyme, Inc.
http://www.epizyme.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Epizyme, Inc.
Ipsen In No Doubt About Its Abilities To Launch
Sales of the French firm’s new products missed consensus forecasts but CEO David Loew is confident that those drugs and the therapies that are close to the market will be commercial successes.
Ipsen Buoyant Despite EMA’s Bylvay Orphan Status Block
The French company plans to refile Bylvay for Alagille syndrome under a new brand name after the EMA's Committee for Orphan Medicinal Products said the drug did not meet its 'significant benefit' criteria.
Ipsen's Desire For Dealmaking Burns Bright
CEO David Loew tells Scrip that valuations to do deals with biotechs “are now at a reasonable level [and] we are screening companies very actively as we speak."
Deal Watch: Moderna, ElevateBio Subsidiary To Combine mRNA With Gene Editing
Moderna and Life Edit will team up to develop transformative or curative therapies for challenging genetic diseases. Erytech and Pherecydes unveil plan to merge and extend runway into 2024.
Company Information
- Industry
- Biotechnology
- Pharmaceuticals
- Other Names / Subsidiaries
-
- Ipsen SA
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice